The approval for sale of the latest VMS+ model. đź‘Ź Dear Friend;
Attached is today’s news release announcing the approval for sale of the latest VMS+ model. Here is some background:
1. The VMS+3.0 is our base version which we have been providing to major hospitals in Canada, Europe and USA and we will continue to provide it as a base model.
2. The VMS+4.0 will be a premium model sold at a premium price, as it does so much more.
3. The more is:
a. broader applicability to all cardiac patients, even those with pacemakers and defibrillators who cannot go into an MRI and so the ability of clinicians to properly assess their hearts has been limited. This is an engineering breakthrough as up to now, the use of the VMS+ in such patients has been a restriction on its use - not any more;
b. automated analysis, which speeds up the analysis process and also provides even more reliability by eliminating operator-operator variability;
c. instantaneous calibration with all existing ultrasound machines, which makes the user experience seamless with the normal cardiac imaging procedure;
d. better 3D visualization of the whole beating heart, which allows the cardiologist to explain to patients exactly how the heart is misfiring and how it can be treated;
e. new detailed measurements of heart function, which allows the clinician to focus in on one chamber of the heart or even one area of the heart and measure its movement and ability to contract.
4. The Company has applied to US-FDA for clearance of the VMS+4.0 in the USA and we a finalizing an application for CE Mark for European approval.
5. The Company will now offer upgrades to its existing customers in Canada as well as marketing it to new hospitals and imaging centers.
Thank you for your interest and support as we continue to improve cardiac diagnostics for everyone, everywhere, and especially for children born with a heart defect.
Regards,
Dr. George Adams ICD.D
Executive-Chairman
Ventripoint Diagnostics Ltd.
TSXV-VPT